Debananda Gogoi

Dr. Debananda Gogoi

Royal College of Surgeons in Ireland
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MOMichael E. O’brien
Michael E. O’brien
GMGrace Murray
Grace Murray
DGDebananda Gogoi
Debananda Gogoi
AYAzeez Yusuf
Azeez Yusuf
CMCormac McCarthy
Cormac McCarthy
EREmer Reeves
Emer Reeves
Alpha-1 antitrypsin (AAT) is the canonical serine protease inhibitor of neutrophil-derived proteases and can modulate innate immune mechanisms through its anti-inflammatory activities mediated by a broad spectrum of protein, cytokine, and cell surface interactions. AAT contains a reactive methionine residue that is critical for its protease-specific binding capacity, whereby AAT entraps the protease on cleavage of its reactive centre loop, neutralises its activity by key changes in its tertiary structure, and permits removal of the AAT-protease complex from the circulation. Recently, however, the immunomodulatory role of AAT has come increasingly to the fore with several prominent studies focused on lipid or protein-protein interactions that are predominantly mediated through electrostatic, glycan, or hydrophobic potential binding sites. The aim of this review was to investigate the spectrum of AAT molecular interactions, with newer studies supporting a potential therapeutic paradigm for AAT augmentation therapy in disorders in which a chronic immune response is strongly linked.


18 July 2016 in RSC Advances
Verified
Journal Article
Closed access
PDF file
DGDebananda Gogoi
Debananda Gogoi
PBPabitra Bhagowati
Pabitra Bhagowati
PGPronob Gogoi
Pronob Gogoi
NBNaba K. Bordoloi
Naba K. Bordoloi
ARAbu Rafay
Abu Rafay
AMAshis Kumar Mukherjee
Ashis Kumar Mukherjee
The present study describes the structural characterization and biotechnological application of a dirhamnolipid biosurfactant produced by Pseudomonas aeruginosa strain NBTU-01 isolated from a petroleum oil-contaminated soil sample. Characterization of partially purified biosurfactant by LC-MS/MS analysis indicated predominant production (78%) of dirhamnolipids Rha-Rha-C10-C10 and Rha-Rha-C12-C10 with a minor production of monorhamnolipids (22%). NMR analysis of the purified major biosurfactant produced by P. aeruginosa strain NBTU-01 identified it as dirhamnolipid and its deduced structure was L-rhamnosyl-L-rhamnosyl-β-hydroxydecanoyl-β-hydroxydecanoate. The LC-MS/MS analysis of intracellular proteins of P. aeruginosa strain NBTU-01 identified key enzymes and other proteins associated with regulation and biosynthesis of rhamnolipids. Critical micelle concentration of purified dirhamnolipid biosurfactant was determined at 72 ± 2.25 mg l−1 and it reduced the surface tension of water from 72.2 to 29.5 mN m−1. The crude rhamnolipid biosurfactant effectively emulsified crude petroleum-oil, diesel, kerosene and coconut oil, and removed 70 ± 3.5% crude petroleum oil from a saturated sand pack column. Heating the crude rhamnolipid biosurfactant at 100 °C for 5 h did not affect oil recovery from the sand pack column. Moreover, rhamnolipid biosurfactant showed stability at pH values between 6.0 and 10.0. The crystallization and melting temperature of purified dirhamnolipid biosurfactant was found to be 99 and 134 °C, respectively, suggesting it can withstand thermal denaturation and is suitable for application in high temperature wells for tertiary oil recovery.

18 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DGDebananda Gogoi
Debananda Gogoi
NANeha Arora
Neha Arora
BKBhargab Kalita
Bhargab Kalita
RSRahul Sarma
Rahul Sarma
TITaufikul Islam
Taufikul Islam
AMAshis Kumar Mukherjee
Ashis Kumar Mukherjee
The harnessing of medicinal plants containing a plethora of bioactive molecules may lead to the discovery of novel, potent and safe therapeutic agents to treat thrombosis-associated cardiovascular diseases. A 35 kDa (m/z 34747.5230) serine protease (lunathrombase) showing fibrin(ogen)olytic activity and devoid of N- and O- linked oligosaccharides was purified from an extract of aqueous leaves from L. indica. The LC-MS/MS analysis, de novo sequencing, secondary structure, and amino acid composition determination suggested the enzyme’s novel characteristic. Lunathrombase is an αβ-fibrinogenase, demonstrating anticoagulant activity with its dual inhibition of thrombin and FXa by a non-enzymatic mechanism. Spectrofluorometric and isothermal calorimetric analyses revealed the binding of lunathrombase to fibrinogen, thrombin, and/or FXa with the generation of endothermic heat. It inhibited collagen/ADP/arachidonic acid-induced mammalian platelet aggregation, and demonstrated antiplatelet activity via COX-1 inhibition and the upregulation of the cAMP level. Lunathrombase showed in vitro thrombolytic activity and was not inhibited by endogenous protease inhibitors α2 macroglobulin and antiplasmin. Lunathrombase was non-cytotoxic to mammalian cells, non-hemolytic, and demonstrated dose-dependent (0.125–0.5 mg/kg) in vivo anticoagulant and plasma defibrinogenation activities in a rodent model. Lunathrombase (10 mg/kg) did not show toxicity or adverse pharmacological effects in treated animals.

1 August 2014 in Biochimie
Verified
Journal Article
Closed access
SMSourav Majumdar
Sourav Majumdar
BSBiplob Sarmah
Biplob Sarmah
DGDebananda Gogoi
Debananda Gogoi
SBSubhamoy Banerjee
Subhamoy Banerjee
SGSiddhartha S. Ghosh
Siddhartha S. Ghosh
AMAshis Kumar Mukherjee
Ashis Kumar Mukherjee

8 November 2018 in Journal of Natural Products
Verified
Journal Article
Closed access
DGDebananda Gogoi
Debananda Gogoi
APAnirban Pal
Anirban Pal
PCPronobesh Chattopadhyay
Pronobesh Chattopadhyay
SPSubrata Paul
Subrata Paul
RDRamesh C. Deka
Ramesh C. Deka
AMAshis Kumar Mukherjee
Ashis Kumar Mukherjee